drugset / Trial / NCT02229461

Naproxen Sodium/ASA Platelet Study

NCT02229461

Phase 1 Completed 117 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

To determine if administration of naproxen sodium 220 mg maintains the platelet inhibitory effect of a low dose Immediate Release Aspirin (IR ASA) regimen.

Timeline

Start
2015-02
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 81 mg
Subject Naproxen Small molecule 220 mg

Indications